MorphoSys AG

560 articles about MorphoSys AG

• MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma

  6/2/2021

  MorphoSys AG (FSE:MOR) announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion.

• MorphoSys to Acquire Constellation Pharmaceuticals

  6/2/2021

  Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209 Bolsters Position in Hematology-Oncology and Expands into Solid Tumors Best-in-Class Combined Discovery and Development Capabilities Accelerates Ability to Provide New Cancer Treatments to Patients MorphoSys Enters into Strategic Funding Partnership with Royalty Pharma

• MorphoSys To Participate in UBS Global Healthcare Conference

  5/21/2021

  MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., the companys Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday May 25, 2021 at 7:00 a.m. Eastern Time.

• MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting

  5/19/2021

  MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new data from the tafasitamab (Monjuvi (R) ) development program will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, 2021.

• MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma

  5/11/2021

  MorphoSys AG and Incyte announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone compared to R-CHOP alone as first-line treatment for high-intermediate and high-risk patients with untreated diffuse large B-cell lymphoma.

• MorphoSys AG Reports First Quarter 2021 Results

  5/5/2021

  For 2021, our focus is on three key areas: executing on the Monjuvi launch; rapidly advancing the tafasitamab backbone strategy through additional clinical studies; and expanding our pipeline," said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys.

• Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021

  4/28/2021

  MorphoSys AG, a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, will publish its results for the first quarter of 2021 on May 5, 2021 at 10:00pm CEST.

• Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

  4/19/2021

  Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

• MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

  4/19/2021

  MorphoSys AG and Incyte announced the first patient has been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma.

• MorphoSys AG Presents Results for Full Year 2020

  3/15/2021

  Conference call and webcast (in English) tomorrow, March 16, 2021 at 2:00pm CET (1:00pm GMT/9:00am EDT) MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) reports results for the year ended December 31, 2020

• Invitation to MorphoSys' Full Year Results 2020 Conference Call on March 16, 2021

  3/9/2021

  MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein, and peptide technologies, will publish its results for the financial year 2020 on March 15, 2021 at 10:00 pm CET (5:00 pm EDT).

• MorphoSys's Licensing Partner GSK Shared Preliminary Results From OSCAR Study with Otilimab for the Treatment of Severe Pulmonary COVID-19 Related Disease

  3/2/2021

  MorphoSys AG , a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today that its licensing partner GlaxoSmithKline plc (LSE/NYSE: GSK) reported preliminary results of the OSCAR (Otilimab in Severe COVID-19 Related Disease) study using otilimab (formerly MOR103/GSK3196165) for the treatment of severe pulmonary COVID-19 related disease.

• Morphosys AG Preliminary Results for the Fiscal Year 2020 Exceeding Guidance

  3/1/2021

  MorphoSys AG announces that according to the analysis of the preliminary results during the ongoing year-end closing process, MorphoSys' outlook has been exceeded.

• MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference

  1/11/2021

  MorphoSys AG, a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday January 13 at 2:50 p.m. EST.

• MorphoSys Appoints Sung Lee as Chief Financial Officer

  1/6/2021

  MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today the appointment of Sung Lee as Chief Financial Officer, effective February 2, 2021.

• MorphoSys AG: Corporate Calendar 2021

  12/17/2020

  MorphoSys AG: Corporate Calendar 2021 Dear Madam/Sir, Please note MorphoSyss financial reporting dates 2021 as follows: Publication of Interim Statement / Report Conference Call Year-End Results 2020 March 15, 2021 // 10 pm CET (5 pm EDT; 9 pm GMT) March 16, 2021 // 2 pm CET (9 am EDT; 1 pm GMT)

• DGAP-News: MorphoSys' Licensee Announces Approval by the European Commission for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA)

  12/2/2020

  MorphoSys AG announced that its licensee Janssen Research & Development, LLC. reported the European Commission's approval for the use of Tremfya in the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug therapy.

• Thomas Biegi Joins MorphoSys As Head of Corporate Communications

  12/1/2020

  MorphoSys Prime Standard Segment; MDAX & TecDAX; announced that Thomas Biegi joins the company as Vice President, Head of Corporate Communications, effective December 1, 2020.

• MorphoSys Reports Nine Months and Third Quarter 2020 Results

  11/11/2020

  Conference call and webcast (in English) to be held on November 12, 2020 at 2:00pm CET (1:00pm GMT/8:00am EST)

• MorphoSys and Cherry Biolabs Announce Licensing of Hemibody Technology

  11/11/2020

  Combination with MorphoSys' antibody know-how enables discovery and development of next-generation T-cell engager molecules